/A%20photo%20of%20a%20Sandisk%20Solid%20State%20Drive%20by%20Top%20Popular%20Vector%20by%20Shutterstock.jpg?ssl=1 "Should You Sell Sandisk Stock Now?")
Transitioned from an R&D-focused entity to a revenue-generating commercial biotech following the FDA approval of Papzimia for adult recurrent respiratory papillomatosis (RRP).
Performance is driven by a broad FDA label that allows treatment of adult RRP patients regardless of prior surgery count or disease severity.
Market uptake is supported by a landmark consensus paper positioning Papzimia as the new standard of care and preferred first-line treatment over traditional surgical intervention.
Revenue growth is accelerating due to the activation of major medical centers and community practices, shifting a century-old surgical management paradigm to medical therapy.
The company achieved significant payer coverage quickly, reaching approximately 215 million lives including major commercial, Medicare, and Medicaid plans.
Strategic prioritization of the pipeline in 2024 resulted in a 22.1% reduction in R&D expenses, allowing for concentrated focus on the Papzimia launch.
Management expects Q1 2026 revenue to exceed $18 million, representing a significant ramp from the $3.4 million recorded in the partial launch quarter of Q4 2025.
The company anticipates reaching cash flow breakeven by the end of 2026, funded by current cash reserves of $100.4 million and projected product sales.
The assignment of a permanent J-code effective April 1, 2026, is expected to streamline billing, reduce provider financial risk, and accelerate patient processing.
Geographic expansion is underway with a Marketing Authorization Application (MAA) currently under review by the EMA for potential European market entry.
Clinical expansion plans include initiating a trial for Papzimia in the pediatric RRP population during the fourth quarter of 2026.
Reported a net loss of $429.6 million for 2025, which includes $318.5 million in non-recurring, non-cash items related to preferred stock conversion and warrant reclassification.
Inventory accounting shift: Post-FDA approval, manufacturing costs for Papzimia are now capitalized as inventory rather than expensed as R&D.
SG&A expenses increased by 69.8% primarily due to a $27.3 million investment in commercial infrastructure and launch activities.
Management explicitly stated they do not intend to provide regular forward-looking revenue guidance beyond the specific Q1 2026 update.
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we’ll show you why it’s our #1 pick. Tap here.
